AUTHORS
Sarah Ducamp, PhD, Juan Putra, MD2, Mark D Fleming, MD, DPhil3
AFFILIATIONS
1 Boston Children's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Introduction. Erythropoietic protoporphyria (EPP) causes acute photosensitivity due to excess production of protoporphyrin IX (PPIX), a phototoxic byproduct of the heme biosynthetic pathway, in red blood cells (RBC). This is due to diminished activity of the last enzyme in the pathway, ferrochelatase (FECH), leading to accumulation of its PPIX substrate. PPIX secondarily accumulates in other tissues. PPIX-related liver disease is unpredictable and can cause hepatic failure. To prevent this accumulation, therapeutic interventions could include either increasing FECH activity or decreasing the synthesis of 5-aminolevulinate (5ALA) by 5-aminolevulinate synthase 2 (ALAS2), the first and rate-limiting enzyme in the pathway. Strategies that either prevent PPIX from accumulating in RBC (Bitopertin) or from being excreted into plasma (ABCG2 knockout) reduce skin PPIX accumulation and photosensitivity and improve liver disease in EPP mouse models, paving the way to ongoing and promising clinical trials.
Rationale. Bitopertin limits the uptake of glycine, which is one of the 2 substrates for ALAS2, by erythroid progenitors. While glycine has other uses in cells than heme biosynthesis, the unique role of ALAS2 is to produce 5ALA, the sole organic precursor to PPIX and heme. Therefore, strategies decreasing ALAS2 expression or activity should prevent PPIX accumulation but limit potential side effects of glycine uptake. X-Linked Sideroblastic Anemia (XLSA) is a genetic disease due to a loss-of-function mutations in ALAS2. In XLSA, 5ALA production in erythroid cells is decreased, ultimately causing microcytic anemia. We hypothesized that EPP animals with an XLSA allele would accumulate less PPIX than EPP animals.
Methods. We crossed EPP (Fechm1Pas) with XLSA (ALAS2R411H) mice to generate C57BL6 male animals that were either XLSA (ALAS2R411H/Y Fechwt/wt), EPP (ALAS2+/Y Fechm1Pas/m1Pas), or EPP-XLSA (ALAS2R411H/Y Fechm1Pas/m1Pas). We monitored RBC PPIX’s mean fluorescence intensity (MFI) by flow cytometry between 1 and 8 weeks of age, performed complete blood counts (CBCs) at 5 and 8 weeks of age, and evaluated liver histology at 8 weeks of age.
Results. In EPP animals, RBC PPIX is 10-fold higher than wildtype littermates at 1 week of age. The PPIX accumulation peaks between 3 and 5 weeks and stabilizes by 8 weeks of age. At 1 week, we observed that EPP-XLSA and EPP animals have the same PPIX levels. The peak PPIX MFI was significantly lower in EPP-XLSA animals and, by 8 weeks of age, their PPIX levels were significantly lower (EPP: 148+/- 52.6 v. EPP-XLSA: 35.5+/-5.7, p-value: 0.0074). Nevertheless, the PPIX levels in EPP-XLSA animals were still higher than in wildtype sex- and age-matched animals, and the mutants retained around 20% PPIX-positive cells in circulation, indicating that the decrease in 5ALA did not entirely compensate for the FECH deficiency. There was, however, substantially less PPIX-induced hepatotocity in EPP-XLSA livers. Surprisingly, the anemia in EPP-XLSA was more severe than in EPP or XLSA animals. At 8 weeks, the hemoglobin (Hb: 9.8+/-0.6 g/dL) and the mean corpuscular hemoglobin (MCH: 8.9+/-0.5 pg) were significantly lower compared to EPP animals (Hb: 12.4+/-0.8 g/dL, MCH: 12.6+/-0.5 pg). The RBC and reticulocyte numbers were significantly increased in EPP-XLSA animals compared to EPP animals, excluding potential hemolysis. These results suggest that, despite the persistent excess of PPIX, less heme was available to produce hemoglobinized RBCs in EPP-XLSA animals.
Discussion. Reducing ALAS2 activity significantly lowers PPIX in EPP RBCs, but worsens anemia, revealing a potential therapeutic tradeoff highly relevant to any potential ALAS2-targeted therapeutic approach. In EPP-XLSA animals, the co-existence of moderate PPIX accumulation with a decrease in Hb is puzzling. There is still too much 5ALA regarding the enzymatic capacity of FECH but not enough heme to produce Hb at levels similar to EPP animals. A decrease in expression or activity of FECH or a decrease in erythroid heme import could explain this result. Despite the theoretical therapeutic potential of ALAS2 inhibition, this study shows that excessive 5ALA deficiency may provide limited additional benefit on PPIX while exacerbating anemia, emphasizing the need for more studies to define a safe therapeutic window for ALAS2-targeted approaches.
DISCLOSURES
Sarah Ducamp, PhD: No relevant conflicts of interest to declare.